Our expertise in cultivation fuels patient wellbeing, delivering CBPMs across distinct medicinal cannabis brands to cater to diverse consumer segments and improve accessibility. This dual-brand strategy widens access and maximises therapeutic impact. CINV’s mission is straightforward: use our resources for the direct betterment of patient health with CBPMs, serving varied needs and ensuring affordability.
Ember Pharms, wholly-owned by CINV, is a leader in full cultivation oversight and management, providing unparalleled expertise in implementing strict SOPs to support partners in producing top tier cultivation results.
We have a South Africa-based SAPHRA-licensed facility which serves as a premier cloning and nursery hub, focusing on phenohunting to develop unique, quality genetics tailored for the medical market.
